This report was first published by Endpoints News. To see the original version, click here
Crescent Biopharma made a set of sweeping moves Thursday morning, notably with its strategy of bringing its PD-1xVEGF to China.
Boston-based Crescent signed a two-way deal with Kelun-Biotech, in which both companies will have access to some of each others’ assets. Crescent said that clinical trial preparation is underway and that it secured a $185 million private placement.
您已閱讀16%（465字），剩余84%（2443字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。